Viacheslav O Nikolaev Selected Research

Guanosine Monophosphate (5' Guanylic Acid)

11/2021	Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia.
1/2020	β3-Adrenoceptor redistribution impairs NO/cGMP/PDE2 signalling in failing cardiomyocytes.
1/2020	Cardiac cGMP Signaling in Health and Disease: Location, Location, Location.
10/2019	cGMP signalling in cardiomyocyte microdomains.
4/2014	Transgenic mice for real-time visualization of cGMP in intact adult cardiomyocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Viacheslav O Nikolaev Research Topics

Disease

14	Heart Failure 10/2022 - 01/2007
6	Cardiomegaly (Heart Hypertrophy) 01/2021 - 11/2011
6	Hypertrophy 01/2020 - 01/2014
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2018
4	Inflammation (Inflammations) 01/2019 - 01/2016
4	Cardiac Arrhythmias (Arrythmia) 09/2016 - 03/2010
3	Hypoxia (Hypoxemia) 11/2021 - 01/2016
3	Atrial Fibrillation 01/2021 - 07/2015
3	Heart Diseases (Heart Disease) 01/2019 - 09/2014
3	Fibrosis (Cirrhosis) 09/2015 - 01/2014
3	Cardiomyopathies (Cardiomyopathy) 01/2015 - 07/2007
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2020 - 07/2007
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2017
2	Lung Diseases (Lung Disease) 01/2020 - 01/2018
2	Muscular Dystrophies (Muscular Dystrophy) 01/2020 - 01/2017
2	Myocardial Infarction 01/2019 - 12/2017
2	Ischemia 12/2017 - 01/2016
2	Takotsubo Cardiomyopathy 08/2017 - 08/2012
1	Necrosis 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Dysferlinopathy 01/2020
1	Chronic Bronchitis 01/2020
1	Bronchitis 01/2019
1	Atherosclerosis 01/2019
1	Lymphoma (Lymphomas) 01/2019
1	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2019
1	Asthma (Bronchial Asthma) 01/2019
1	Reperfusion Injury 12/2017
1	Tachycardia (Tachyarrhythmias) 11/2017
1	Genetic Predisposition to Disease (Genetic Predisposition) 08/2017
1	Thrombocytopenia (Thrombopenia) 01/2017
1	Hemorrhage 01/2017

Drug/Important Bio-Agent (IBA)

6	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021 - 10/2012
6	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2020 - 01/2015
5	Adenosine Monophosphate (AMP)IBA 11/2021 - 07/2007
5	Guanosine Monophosphate (5' Guanylic Acid)IBA 11/2021 - 04/2014
4	Natriuretic PeptidesIBA 10/2022 - 04/2015
4	Pharmaceutical PreparationsIBA 01/2019 - 07/2014
4	Adrenergic Agents (Adrenergic Drugs)IBA 08/2017 - 10/2012
4	Atrial Natriuretic Factor (ANF)IBA 01/2016 - 11/2011
3	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2015
3	AntibodiesIBA 01/2020 - 07/2007
3	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2017 - 10/2012
2	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 10/2020
2	Protein Isoforms (Isoforms)IBA 01/2020 - 10/2012
2	Phosphodiesterase 4 InhibitorsIBA 01/2020 - 01/2019
2	RoflumilastIBA 01/2020 - 01/2019
2	Soluble Guanylyl CyclaseIBA 01/2020 - 12/2017
2	DysferlinIBA 01/2020 - 01/2017
2	AutoantibodiesIBA 01/2020 - 07/2007
2	SmokeIBA 01/2020 - 01/2018
2	diethylstilbestrol monophosphate (PDES)IBA 01/2019 - 01/2018
2	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 12/2017 - 01/2014
2	CatecholaminesIBA 08/2017 - 10/2012
2	Cyclic NucleotidesIBA 07/2017 - 01/2017
2	Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA 07/2015 - 07/2014
2	beta Adrenergic ReceptorsIBA 10/2013 - 01/2007
2	CalciumIBA 10/2012 - 10/2011
1	RNA (Ribonucleic Acid)IBA 10/2022
1	MyokinesIBA 10/2022
1	LipopolysaccharidesIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022
1	Serotonin (5 Hydroxytryptamine)IBA 01/2021
1	LipidsIBA 01/2021
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 10/2020
1	Neprilysin (Neutral Endopeptidase)IBA 10/2020
1	EpitopesIBA 01/2020
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 01/2020
1	cilostamideIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	CalcineurinIBA 01/2020
1	Complex MixturesIBA 01/2020
1	DisulfidesIBA 01/2020
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2020
1	FenoterolIBA 01/2020
1	RolipramIBA 01/2020
1	polyprolineIBA 01/2020
1	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)IBA 01/2019
1	Adenosine Triphosphatases (ATPase)IBA 01/2019
1	Adenine NucleotidesIBA 01/2019
1	Histones (Histone)IBA 01/2019
1	SodiumIBA 01/2019
1	phospholemmanIBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 12/2017
1	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 12/2017
1	Acetylcholine (Acetylcholine Chloride)FDA Link 11/2017
1	Atropine FDA LinkGeneric 11/2017
1	Neurotransmitter Agents (Neurotransmitter)IBA 11/2017
1	Cholinergic Antagonists (Anticholinergics)IBA 11/2017
1	NM23 Nucleoside Diphosphate KinasesIBA 02/2017
1	GTP-Binding Proteins (G-Protein)IBA 02/2017
1	ABT-737IBA 01/2017
1	navitoclaxIBA 01/2017
1	thymoquinoneIBA 01/2017

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2015
1	Drug Therapy (Chemotherapy) 01/2017
1	Combination Drug Therapy (Combination Chemotherapy) 01/2017
1	Sympathectomy (Sympathectomies) 01/2017